The newest deal comes from Polish-founded uFraction8, based in Falkirk, UK.
👯 Founder(s): Dr. Monika Tomecka and Dr. Brian Miller
📅 Founding year: 2017
🏭 Industry: Biotech, CleanTech
💥 Problem: Biomanufacturing processes for food, pharmaceuticals, and bio-based products rely on energy-intensive and inefficient filtration methods.
📣 Solution: uFraction8 has developed microfluidics-based filtration systems that optimize cell and biomass production, providing a scalable, energy-efficient alternative.
👥 Customers: Bio-manufacturers in microalgae, cultivated meat, and biopharma sectors
🎳 Team size: Currently employs 7 people within its business in Scotland and Poznan, Poland.
🌱 Stage: Growth
💰 Investment amount: €4.12M (£3.4M)
💡 It will be spent on…
Commercializing uFraction8’s technology originally developed at the University of Edinburgh’s School of Engineering, supporting further tech development, and reducing costs in microalgae and biopharma production.
💬 In their own words:
“These funds will ensure we can bring our solutions to market more rapidly, particularly within the microalgae and biopharma sectors, and enable uFraction8 to continue its innovation within the alternative protein sector.”
— Dr. Monika Tomecka, Founder and CEO
🚀 Funded by: Foresight Group (UK), Old College Capital (University of Edinburgh’s in-house venture investment fund), Scottish Enterprise, Alwyn Capital, Thia Ventures, and a grant from the Polish Agency for Enterprise Development
👁️🗨️ Investor’s perspective:
“uFraction8’s advancements in continuous bioprocessing present transformative opportunities across multiple industries. We are excited to help the company achieve further impact in their important work.”
— Rubina Singh, Senior Investment Manager at Foresight Group
💪 Their specialty…
uFraction8 leverages hydrodynamic phenomena for filtration, surpassing conventional systems in efficiency and scalability. The company simplifies bioprocessing for food, bio-pharmaceuticals, and bio-based products.
🔑 Business model:
B2B sales of proprietary microfluidics-based filtration systems to bio-manufacturers
👩🏫 Market:
Bio-separation in biopharma (expected to reach $30B by 2030) and microalgae processing ($3B by 2030)
📊 Traction:
Secured €3.03M (£2.5M) in an earlier 2022 funding round led by Thia Ventures.
📈 Funding so far: €7.14M (£5.9M), including this round.
